NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination of three antiretroviral agents (stavudine, lamivudine, and efavirenz) for the treatment of HIV-1 infection. The combination works through multiple mechanisms: stavudine and lamivudine are nucleoside reverse transcriptase inhibitors, while efavirenz is a non-nucleoside reverse transcriptase inhibitor. This regimen targets HIV replication by blocking reverse transcriptase activity.
Pre-Launch
Pre-launch stage with undetermined commercial trajectory; team composition and scale remain contingent on regulatory approval and market entry strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch product offers early-career professionals an opportunity to be part of a regulatory transition to market entry. Positions will emphasize launch readiness, market access strategy, and post-approval compliance in the competitive HIV treatment space.
Regulatory Affairs SpecialistCommercial Operations Manager
Worked on STAVUDINE; LAMIVUDINE; EFAVIRENZ at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.